End of Government Purchasing, PHE Could Lead to Access, Pricing Issues for COVID Treatments

Since the COVID-19 pandemic began, the federal government has spent tens of billions of dollars purchasing vaccines, treatments and tests and providing them for free to the public. Congress has also passed legislation ensuring private and public payers cover those countermeasures for as long as the public health emergency (PHE) is in place.

However, that may soon be ending as Congress has yet to authorize additional COVID-specific funding and the PHE is likely to expire sometime next year. That could lead to questions about access, pricing and insurance coverage, according to panelists who spoke during a Kaiser Family Foundation (KFF) webinar on Oct. 19.

© 2024 MMIT
Freelance Reporter

Freelance Reporter Freelance Reporter

Related Posts

people-getting-vaccination
October 14

COVID Booster Campaign Could Prevent Thousands of Deaths, Save Billions in Medical Costs

READ MORE
white-house
August 25

Insurers Brace for When U.S. Stops Buying COVID-19 Vaccines, Therapeutics

READ MORE
covid-pills
February 10

ICER Draft Report Deems Four COVID Drugs Reasonably Priced

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today